Patents by Inventor William B. Weglicki

William B. Weglicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of NK-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with EGFR-blocking drugs
    Patent number: 9687493
    Abstract: The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: June 27, 2017
    Assignee: THE GEORGE WASHINGTON UNIVERSITY
    Inventors: William B. Weglicki, Iu Tong Mak
  • USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING HYPOMAGNESEMIA, NEUROGENIC INFLAMMATION, AND CARDIAC DYSFUNCTION ASSOCIATED WITH EGFR-BLOCKING DRUGS
    Publication number: 20170014420
    Abstract: The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Applicant: THE GEORGE WASHINGTON UNIVERSITY
    Inventors: William B. WEGLICKI, Iu Tong MAK
  • Use of NK-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with EGFR-blocking drugs
    Patent number: 9474761
    Abstract: The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: October 25, 2016
    Assignee: THE GEORGE WASHINGTON UNIVERSITY
    Inventors: William B. Weglicki, Iu Tong Mak
  • USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING HYPOMAGNESEMIA, NEUROGENIC INFLAMMATION, AND CARDIAC DYSFUNCTION ASSOCIATED WITH EGFR-BLOCKING DRUGS
    Publication number: 20150352120
    Abstract: The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.
    Type: Application
    Filed: June 10, 2015
    Publication date: December 10, 2015
    Inventors: William B. WEGLICKI, Iu Tong MAK
  • Racemic propranolol
    Patent number: 6121328
    Abstract: Pharmaceutical formulations of mixtures of the D and L configuration of propranolol are disclosed which have antioxidant activity and reduced .beta. blocking activity.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: September 19, 2000
    Assignee: The George Washington University
    Inventor: William B. Weglicki
  • Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution
    Patent number: 6100297
    Abstract: The intravenous use of magnesium gluconate to substantially block free radical surge in the treatment of ischemia/reperfusion (I/R) injury due to oxidative stress.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: August 8, 2000
    Assignee: The George Washington University
    Inventor: William B. Weglicki
  • Racemic propranolol
    Patent number: 5919828
    Abstract: Pharmaceutical formulations of mixtures of the D and L configuration of propranolol are disclosed that have antioxidant activity and reduced .beta. blocking activity.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: July 6, 1999
    Inventor: William B. Weglicki
  • D-Propranolol metabolites useful for antioxidant activities
    Patent number: 5854287
    Abstract: Metabolites of the D-isomer of propranolol show potent antioxidant activity, independent of .beta.-blocker activity, that make them useful for the treatment of all conditions that can be treated by antioxidants, or any disease that is responsive to antioxidant treatment, for example, diseases or disorders of the cardiovascular system, heart failure, myocardial infraction, atherosclerosis, stroke, hypertension, ischemia/reperfusion injury an inflammatory processes.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: December 29, 1998
    Inventor: William B. Weglicki
  • Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution
    Patent number: 5843996
    Abstract: The intravenous use of magnesium gluconate to substantially block free radical surge in the treatment of ischemia/reperfusion (I/R) injury due to oxidative stress is disclosed.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: December 1, 1998
    Inventor: William B. Weglicki
  • Fluorinated propranolol and related methods
    Patent number: 5776985
    Abstract: Fluorinated beta blockers, such as propranolol, are presented with amplified antioxidant effects and various levels of beta blocking effects. Mixtures are also presented of fluorinated antioxidant drugs, such as propranolol, with fluorinated antioxidant non-beta blocking analogs of the same drugs. Methods of treatment of disease by the use of the fluorinated drugs and the mixtures are presented.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: July 7, 1998
    Assignee: The George Washington University
    Inventors: William B. Weglicki, I. T. Mak, Hassan Y. Aboul-Enein